Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Production of Pharmaceuticals

Production of Pharmaceuticals

Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under sterile, tightly...

Modified-Release Drug Delivery Systems: Rate-Programmed II

Modified-Release Drug Delivery Systems: Rate-Programmed II

Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...

Upstream Processing

Upstream Processing

Upstream processing represents a critical phase in biomanufacturing, wherein biological systems such as microorganisms, mammalian cells, or insect cells are cultivated to produce therapeutic proteins, vaccines, enzymes, or other biologically derived products. This phase encompasses all steps from the selection and genetic manipulation of the production organism to the cultivation of cells in bioreactors under tightly controlled environmental conditions.Host Selection and Genetic OptimizationThe...

Modified-Release Drug Delivery Systems: Rate-Programmed I

Modified-Release Drug Delivery Systems: Rate-Programmed I

Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...

Modified-Release Drug Delivery Systems: Overview

Modified-Release Drug Delivery Systems: Overview

Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...

Bioreactor Controls-III

Bioreactor Controls-III

Strain improvement is a foundational strategy in industrial microbiology aimed at maximizing microbial productivity, particularly because natural isolates typically yield commercially valuable products in very low concentrations. Although optimizing the culture medium and environmental conditions can improve yields, these adjustments are inherently limited by the organism’s genetic potential. As a result, the focus shifts toward genetic modifications to enhance biosynthetic capacity. The...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Observation of In-Ice Askaryan Radiation from High-Energy Cosmic Rays.

Physical review letters·2026

Same author

[Burn-out, commitment, personality and experiences during work and training; survey among psychiatry residents].

Tijdschrift voor psychiatrie·2017

Same author

Ischemia-Reperfusion Injury Enhances Lymphatic Endothelial VEGFR3 and Rejection in Cardiac Allografts.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2015

Same author

Removal of rotavirus and adenovirus from artificial ground water using hydrochar derived from sewage sludge.

Journal of applied microbiology·2015

Same author

Donor Heart Treatment With COMP-Ang1 Limits Ischemia-Reperfusion Injury and Rejection of Cardiac Allografts.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2015

Same author

Angiopoietin-2 inhibition prevents transplant ischemia-reperfusion injury and chronic rejection in rat cardiac allografts.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2014

Search research articles

Related Experiment Video

Updated: Jun 21, 2026

Process Optimization using High Throughput Automated Micro-Bioreactors in Chinese Hamster Ovary Cell Cultivation

Process Optimization using High Throughput Automated Micro-Bioreactors in Chinese Hamster Ovary Cell Cultivation

Published on: May 18, 2020

Novel technology to improve pharmaceutical productivity.

¹Boehringer Ingelheim GmbH, Binger Strasse, Postfach 200, D-55216 Ingelheim, Germany. krebs@ing.boehringer-ingelheim.com

Current Opinion in Drug Discovery & Development

|August 4, 2009

Summary

This summary is machine-generated.

Pharmaceutical R&D productivity is shifting due to high-throughput screening and data management. Organizational changes and teamwork are crucial for future success and overcoming limitations in drug discovery.

More Related Videos

Optimization of Radiochemical Reactions using Droplet Arrays

Optimization of Radiochemical Reactions using Droplet Arrays

Published on: February 12, 2021

A High-throughput Automated Platform for the Development of Manufacturing Cell Lines for Protein Therapeutics

A High-throughput Automated Platform for the Development of Manufacturing Cell Lines for Protein Therapeutics

Published on: September 22, 2011

Related Experiment Videos

Last Updated: Jun 21, 2026

Process Optimization using High Throughput Automated Micro-Bioreactors in Chinese Hamster Ovary Cell Cultivation

Process Optimization using High Throughput Automated Micro-Bioreactors in Chinese Hamster Ovary Cell Cultivation

Published on: May 18, 2020

Optimization of Radiochemical Reactions using Droplet Arrays

Optimization of Radiochemical Reactions using Droplet Arrays

Published on: February 12, 2021

A High-throughput Automated Platform for the Development of Manufacturing Cell Lines for Protein Therapeutics

A High-throughput Automated Platform for the Development of Manufacturing Cell Lines for Protein Therapeutics

Published on: September 22, 2011

Area of Science:

Pharmaceutical Sciences
Information Technology in R&D
Organizational Management

Background:

Literature review from 1997-1998 indicates a paradigm shift in pharmaceutical discovery.
Increased data volume necessitates advanced information technology solutions for R&D efficiency.

Purpose of the Study:

To outline progress in pharmaceutical R&D productivity.
To discuss future directions and limitations in enhancing R&D efficiency.

Main Methods:

Literature review of scientific publications from late 1997 to end of 1998.
Analysis of key factors influencing pharmaceutical R&D productivity.

Main Results:

Combined use of high-throughput screening systems is a key factor.
Information technology is central to driving R&D efficiency.
Organizational structures and teamwork are increasingly important.

Conclusions:

The pharmaceutical industry is evolving its discovery process.
Future R&D productivity depends on technological integration, organizational adaptation, and collaborative efforts.
Addressing limitations requires strategic advancements in these key areas.